Rituximab
- PDF / 168,995 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 50 Downloads / 143 Views
1 S
Infusion-related reactions following off-label therapy: 2 case reports In a multicenter, retrospective study involving 355 patients (started rituximab treatment from January 2009 until May 2019), two patients [ages and sexes not stated] were described, who developed infusion-related reaction (1 patient) and serious infusion-related allergic reaction (1 patient) during off-label therapy with rituximab for multiple sclerosis [dosages and durations of treatment to reactions onset not stated]. One of these patients completed rituximab induction phase, while the remaining one patient’s rituximab was stopped during induction phase [outcomes not stated] Zecca C, et al. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. Multiple Sclerosis Journal 26: 1519-1531, No. 12, 1 Oct 2020. 803518164 Available from: URL: http://doi.org/10.1177/1352458519872889
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
